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Abstract
Rearrangement of chromosome band 6p21 is recurrent in endometrial stromal sarcoma (ESS) and targets the PHF1 gene. So
far, PHF1 was found to be the 39 partner in the JAZF1-PHF1 and EPC1-PHF1 chimeras but since the 6p21 rearrangements
involve also other chromosomal translocation partners, other PHF1-fusions seem likely. Here, we show that PHF1 is
recombined with a novel fusion partner, MEAF6 from 1p34, in an ESS carrying a t(1;6)(p34;p21) translocation as the sole
karyotypic anomaly. 59-RACE, RT-PCR, and sequencing showed the presence of an MEAF6-PHF1 chimera in the tumor with
exon 5 of MEAF6 being fused in-frame to exon 2 of PHF1 so that the entire PHF1 coding region becomes the 39 terminal part
of the MEAF6-PHF1 fusion. The predicted fusion protein is composed of 750 amino acids and contains the histone
acetyltransferase subunit NuA4 domain of MEAF6 and the tudor, PHD zinc finger, and MTF2 domains of PHF1. Although the
specific functions of the MEAF6 and PHF1 proteins and why they are targeted by a neoplasia-specific gene fusion are not
directly apparent, it seems that rearrangement of genes involved in acetylation (EPC1, MEAF6) and methylation (PHF1),
resulting in aberrant gene expression, is a common theme in ESS pathogenesis.
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Introduction
Endometrial stromal sarcomas (ESS) are rare malignancies that
account for less than 10% of uterine sarcomas [1]. Cytogenetic
analysis has been reported in 47 cases of ESS and has revealed
three recurrent karyotypic features: 1) Chromosomal translocation
t(7;17)(p15,p21;q12,q21) in 12 cases (25.5%); 2) Rearrangement
of the short arm of chromosome 6, particularly band 6p21, in 12
cases (25.5%); and 3) Chromosomal translocation
t(10;17)(q22;p13) in 10 cases (21%) [2,3]. A recent study showed
that tumors having the t(10;17)(q22;p13), which gives rise to
YWHAE-FAM22A or YWHAE-FAM22B fusion genes, have gene
expression profiles different from those normally seen in ESS [3].
Current terminology refers to this former subset of ESS as high
grade sarcoma NOS [4].
Molecular studies of the t(7;17) have shown that the transloca-
tion leads to the fusion of two zinc finger genes, JAZF1 and SUZ12
(also named JJAZ1) [5]. Subsequent studies of larger tumor series
using RT-PCR and fluorescence in situ hybridization (FISH) have
shown the occurrence of the JAZF1/SUZ12 fusion gene not only
in ESS but also in endometrial stromal nodules and, less
frequently, in undifferentiated endometrial sarcomas [6,7,8,9].
The translocations giving rise to 6p21 rearrangements have
differed among ESS tumors. Chromosome 7 has been involved the
most with breaks mapping to bands 7p22, 7p21, 7q11, 7q21, and
7q34, the chromosome bands 3p13 and 3q29 were reported to be
involved in two tumors each, a der(15)t(6;15)(p21;p12) was found
in one tumor, and an add(6)(p21) was described in yet another case
[2]. Micci et al [10] showed that in ESS with 6p21 aberrations the
target gene is PHF1 which codes for a protein with significant
sequence similarities to Drosophila Polycomblike. This gene was
reported to become the 39partner in two chimeras: a JAZF1-PHF1
found in two tumors showing a 6p;7p-rearrangement, and an
EPC1-PHF1 (EPC1 is located at 10p11) in a third tumor with a
6;10;10-translocation as the sole karyotypic abnormality [10].
JAZF1-PHF1 fusion genes have since been described in 5
additional ESS [11,12] and EPC1-PHF1 in 3 more ESS, 2 uterine
and 1 extrauterine [11]. PHF1 rearrangements were found in 5
additional ESS but with unknown partner genes [11]. The
consistent involvement of PHF1 suggests that this gene plays an
important role in the development of a subset of ESS. However,
both the cytogenetic and molecular data suggest the existence of
so-far unknown, additional partner genes for PHF1 rearrange-
ments. In the present study, we describe an ESS in which PHF1
was recombined with a novel fusion partner, MEAF6, from 1p34.
Results
G-banding and FISH Findings
The G-banding and FISH analyses yielded the karyotype
46,XX,t(1;6)(p32,34;p21) (Figure 1A). When metaphase spreads
were hybridized with the PHF1-specific probe, a split signal was
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6 was within the PHF1 locus (Figure 1B). FISH with a BAC probe
containing the MEAF6 locus on chromosome 1 showed that
MEAF6 had moved to the derivative chromosome 6 (Figure 1B).
Molecular Genetic Findings
59-RACE methodology amplified a single 1 kb fragment
(Figure 1D). Sequence analysis showed that the fragment was a
hybrid cDNA product in which exon 5 of the MEAF6 gene (nt 550
in NM_022756 version 4), from sub-band 1p34.3, was fused in-
frame to exon 2 of PHF1 (nt 200 in NM_024165 version 2), from
sub-band 6p21.32 (Figure 1E). Subsequently, RT-PCR with the
MEAF6-322F/PHF1-380R primer combination amplified a
435 bp cDNA fragment, whereas amplification with the
MEAF6-460F/PHF1-327R primer combination generated a
241 bp cDNA fragment (Figure 1F). The fragments were analyzed
by direct sequencing which verified the presence of a MEAF6-
PHF1 chimeric transcript. A reciprocal PHF1-MEAF6 cDNA
fragment, looked for using two primer sets (PHF1-18F/MEAF-
729R and PHF1-136F/MEAF6-700R), was not amplified. Geno-
mic PCR amplified a 2.5 kb genomic fragment (Figure 1F). Partial
sequencing showed that the breakpoints were located in intron 5 of
MEAF6 and intron 1 of PHF1 (Figure 1E). A reciprocal PHF1/
MEAF6 genomic fragment using PHF1 forward primers in exon 1
and MEAF6 reverse primers in exon 6 was not amplified (data not
shown).
Discussion
In the present study we showed that PHF1 was rearranged and
fused to a novel partner gene, MEAF6, as the result of a
t(1;6)(p34;p21) occurring as the sole chromosomal aberration in an
ESS. This recombination has extensive similarities with the other
two PHF1 chimeras, JAZF1-PHF1 and EPC1-PHF1, found in ESS
[10,12]. At the genomic level: 1) MEAF6 and PHF1 are
Figure 1. Cytogenetic, FISH, and PCR analyses of the metastasis from the endometrial stromal sarcoma. A) Partial karyotype showing
chromosome aberrations der(1)t(1;6)(p34;p21) and der(6)t(1;6)(p34;p21) together with the corresponding normal chromosomes; breakpoint position
are indicated by arrows. B) FISH using BAC RP11-508M23 (green signal) from 1p34 containing the MEAF6 gene and a pool of the RP11-600P03 and
RP11-436J22 BACs (red signal) from 6p21 containing the PHF1 gene. A part of the probe from 6p21 (red signal) has moved to the derivative
chromosome 1, while the entire probe containing MEAF6 has moved to the derivative chromosome 6. The data suggest that the functional fusion
gene is generated on the der(6). C) G-banding of the metaphase spread shown in (B). D) Amplification of a 1 kb cDNA in the 59-RACE analysis (R)
using reverse PHF1-721R and PHF1-526R primers and the universal forward primers. E) Partial sequence chromatograms of the 1 kb cDNA fragment
showing the junctions (arrow) of MEAF6-PHF1 chimeric transcript (upper) and genomic hybrid DNA fragment (lower). F) RT-PCR and genomic PCR
using specific MEAF6 and PHF1 primers. Lane 1: Amplification of MEAF6-PHF1 cDNA fragment with MEAF6-322F/PHF1-380R primers, lane 2:
Amplification of MEAF6 transcript with MEAF6-15F/MEAF6-700R, lane 3: PHF1-18F/MEAF6-729R primer set did not amplify the reciprocal PHF1-MEAF6
cDNA, lane 4: Amplification of PHF1 transcript with PHF1-18F/PHF1-327R primers, lane 5: Amplification of MEAF6-PHF1 genomic hybrid DNA fragment
with MEAF6-371F/PHF1-302R primer combination. M, 1 kb DNA ladder.
doi:10.1371/journal.pone.0039354.g001
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genomic events are required for the formation of a functional
MEAF6-PHF1 fusion as has been described also for JAZF1-PHF1
and EPC1-PHF1 [10,12]; 2) the breakpoint in PHF1 occurred in
intron 1 similarly to what happens in the fusions with JAZF1 and
EPC1. This intron is 1032 bp long and contains an AluSg repeat;
and 3) the reciprocal PHF1-MEAF6 chimera could not be detected
suggesting its absence or that it has undergone complex genetic
changes rendering it undetectable by PCR. At the transcriptional
level, MEAF6-PHF1 seemed to be the chimeric transcript of
tumorigenic importance since RT-PCR did not amplify the
reciprocal PHF1-MEAF6 transcript. Similarly to what has been
described for the JAZF1-PHF1 and EPC1-PHF1 fusion genes in
ESS, the entire PHF1 coding region becomes the 39 terminal part
of the MEAF6-PHF1 fusion which gives a predicted fusion protein
of 750 amino acids containing the histone acetyltransferase subunit
NuA4 domain of MEAF6 and the tudor, PHD zinc finger and
MTF2 domains of PHF1.
The MEAF6 gene acting as the 59-partner in the fusion is
ubiquitously and abundantly expressed and encodes a protein
which is part of the TIP60-ING3, HBO1-ING4/5, and MOZ/
MORF histone acetyltransferase (HAT) multi-subunit complexes
of the MYST family [13,14,15]. The MYST histone acetyltrans-
ferases are highly conserved in eukaryotes and carry out a
significant proportion of all nuclear acetylation. TIP60-ING3 is
responsible for acetylation of histones H4 and H2A, HBO1-
ING4/5 for histone H3 and H4 acetylation, and MOZ/MORF
histone acetyltransferase for H3 acetylation. They function
exclusively in multisubunit protein complexes and play critical
roles in gene-specific transcription regulation, DNA damage
response and repair, as well as DNA replication [16,17]. In the
TIP60-ING3 complex, MEAF6 physically interacts with the EPC1
protein shown to be fused to the entire coding sequence of PHF1
in the EPC1-PHF1 chimera [16,17].
PHF1 encodes a Polycomb group (PcG) protein that contains a
tudor domain, PHD zinc finger domains, and a polycomb-like
MTF2 factor 2 domain [18]. PcG proteins are thought to form a
multimeric complex that modifies local chromatin structure and
establishes a heritable repression state at particular loci.
Tudor domains of several chromatin related proteins interact
with various methylated lysine and arginine residues [19]. The
plant homeodomain (PHD) finger is a C4HC3 zinc-finger-like
motif found in nuclear proteins thought to be involved in
epigenetics and chromatin-mediated transcriptional regulation
[20]. Mammalian Polycomb-like protein MTF2/PCL2 forms a
complex with Polycomb repressive complex-2 (PRC2) and
collaborates with PRC1 to achieve repression of Hox gene
expression [21].
PHF1 is a component of a histone H3 lysine-27 (H3K27)
specific methyltransferase complex and is important for Hox gene
expression in vivo [22,23]. Hong et al [24] showed that PHF1 is
also recruited to DNA double strand breaks and interacts
physically with many proteins which are involved in DNA damage
response. Although the specific functions of the MEAF6 and PHF1
in the neoplastic context and why they are involved in an ESS-
specific fusion are not directly apparent, one can assume a
mechanism similar to the EPC1-PHF1 proposed by Avvakumov
and Co ˆte ´ [16], namely that the MEAF6-PHF1 chimeric protein
diverts HAT activity towards PHF1’s normal genomic targets.
Mistargeted acetylation would lead to loosening up of the
heterochromatin, resulting in aberrant gene expression that could
eventually lead to a malignant phenotype.
Although the t(1;6)(p34;p21) presented here has never been
reported before in ESS, a t(1;6)(p32–33;p21.3) was found as the
sole clonal cytogenetic abnormality in what was called a uterine
leiomyosarcoma [25]. Additionally, involvement of chromosome
arm 1p was reported in four ESS [26,27,28,29]. Since the
formation of a functional MEAF6-PHF1 chimera requires
complex genomic events, the presence of hidden MEAF-PHF1
fusions in ESS whose karyotypes include 1p rearrangements or




A 43-year-old female presented with a tumor in the uterus and a
total hysterectomy was performed. The histological diagnosis was
endometrial stromal sarcoma and macroscopic evaluation showed
multiple nodules in the myometrium and a 13 cm large tumor on
the outer aspect of the uterus. After four years of follow-up,
metastases in the pelvic region were detected and a resection was
made. Seven months after the metastasectomy the patient is in
remission.
Microscopic examination of the primary tumor showed a
relatively monotonous, diffusely infiltrating growth pattern with
variable cellularity and bland, uniform spindle cells. Small vascular
structures were seen. There was no necrosis or vessel infiltration
(Figure 2). Immunohistochemical examination showed strong
staining for vimentin, CD10, h-caldesmon, PGR and focally for
SMA, ER and desmin, but negative results for CD117, S-100, and
pan-cytokeratin (AE1/AE3). The metastasis displayed the same
morphological appearance.
The study was approved by the Regional komite ´ for medisinsk
forskningsetikk Sør- Norge (REK Sør, http://helseforskning.
etikkom.no), and written informed consent was obtained from
the patient.
G-banding and Karyotyping
Tumor tissue removed during surgery directed against the
metastases was processed for cytogenetic analysis using standard
methods [30]. Chromosome preparations made from metaphase
cells of a week-old culture were G-banded using Wright stain and
karyotyped according to ISCN 2009 guidelines [31].
Fluorescence in situ Hybridization Analyses
BAC clones were retrieved from the RPCI-11 Human BAC
library (BACPAC Resources, http://bacpac.chori.org/home.
htm). They were selected according to physical and genetic
mapping data on chromosomes 1 and 6 (see below) as reported on
the Human Genome Browser at the University of California,
Santa Cruz website (May 2004, http://genome.ucsc.edu/). In
addition, FISH mapping of the clones on normal controls was
performed to confirm their chromosomal location. The clones
used were RP11-508M23 mapping to 1p34.3 which contains the
MEAF6 gene, and RP11-600P03 and RP11-436J22 mapping to
6p21.32–6p21.31 for PHF1. DNA was extracted and probes were
labelled and hybridized as previously described [32]. Chromosome
preparations were counterstained with 0.2 mg/ml DAPI and
overlaid with a 24650 mm
2 coverslip. Fluorescent signals were
captured and analyzed using the CytoVision system (Applied
Imaging, Newcastle, UK).
Molecular Genetic Analyses
59-Rapid amplification of cDNA ends. The primers used
for PCR amplification and sequencing are listed in Table 1. Total
RNA and genomic DNA were extracted using Trizol reagent
according to the manufacturer’s instructions (Invitrogen). Two mg
MEAF6-PHF1 Fusion in Endometrial Stroma Sarcoma
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was performed using the GeneRacer kit (Invitrogen) according to
the manufacturer’s protocol. In brief, the ligated RNA was reverse
transcribed using Cloned Avian Myeloblastosis Virus reverse
transcriptase (Cloned AMV RT) and first round polymerase chain
reaction (PCR) was done with the forward GeneRacer 59Primer
and PHF1-721R reverse primer. Second round PCR was
performed with the forward GeneRacer 59Nested Primer and
the primer PHF1-526R. For PCR the AccuPrime Taq DNA
Polymerase High Fidelity was used (Invitrogen). The template
(1 mL cDNA) was amplified in a 50 mL volume containing 0.2 mM
of each forward and reverse primer, 16AccuPrime PCR buffer I,
and 1.25 U AccuPrime Taq DNA Polymerase High Fidelity. One
mL of the PCR products was re-amplified in a second PCR using
0.2 mM of each GeneRacer 59Nested Primer and the reverse
primer PHF1-526R. After an initial denaturation for 1 min at
94uC, 30 cycles of 15 s at 94uC, 30 s at 56uC (63uC for nested
PCR), and 3 min (1 min for nested PCR) at 68uC were run,
followed by a final extension for 5 min at 68uC. Fifteen mL of the
PCR products were analyzed by electrophoresis through 1.5%
agarose gels, stained with GelRed (Biotium), and photographed.
The amplified products were excised from the gel, purified using
the Qiagen gel extraction kit (Qiagen), and cloned to pCR4-
TOPO vector using TOPO TA Cloning Kits for Sequencing
Figure 2. Microscopic examination of the primary endometrial stromal sarcoma. A–C: H&E-stained sections of the tumor (A, B: x50
magnification; C: x100 magnification); D: Positive immunostaining for CD10 (x100 magnification).
doi:10.1371/journal.pone.0039354.g002
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procedure with an ABI Prism BigDye terminator v1.1 cycle
sequencing kit (PE Applied Biosystems) on the Applied Biosystems
Model 3100-Avant DNA sequencing system. The BLAST
software (http://www.ncbi.nlm.nih.gov/BLAST/) was used for
computer analysis of sequence data.
PCR Analyses
Two mg of total RNA were reverse-transcribed in a 20 mL
reaction volume using iScript Advanced cDNA Synthesis Kit for
RT-qPCR according to the manufacturer’s instructions (Biorad).
The cDNA was diluted to 100 mL and 2 mL were used as
templates in subsequent PCR assays. A one-step PCR was
performed for amplification of the MEAF6/PHF1 and possible
reciprocal PHF1/MEAF6 fusion transcripts as well as normal
MEAF6 and PHF1 transcripts. The 50 mL PCR volume contained
2 mL of cDNA, 1x LA PCR Buffer II (Mg
2+ plus), 0.4 mM of each
dNTP, 2.5 unit TaKaRa LA Taq (TaKaRA), and 0.6 mM of each
of the forward and reverse primers. For amplification of the
MEAF6/PHF1 fusion transcript the MEAF6-322F/PHF1-380R
and MEAF6-460F/PHF1-327R primer combinations were used.
For amplification of the MEAF6 transcript the primers MEAF-
423F/MEAF6-729R were used, and for amplification of PHF1
cDNA the primer set PHF1-18F/PHF1-327R was used. For a
possible reciprocal PHF1/MEAF6 transcript the primer sets
PHF1-18F/MEAF-729R and PHF1-136F/MEAF6-700R were
used.
For genomic PCR the 50 mL PCR volume had the same
composition as above except that 100 ng DNA were used as
template. For the detection of genomic MEAF6-PHF1 and PHF1-
MEAF6 hybrids the primer sets MEAF6-460F/PHF1-729R and
PHF1-136F/2MEAF6-700R were used.
The PCRs were run on a C-1000 Thermal cycler (Biorad). The
PCR conditions were: an initial denaturation at 94uC for 1 min,
followed by 30 cycles of 7 sec at 99uC and 1 min at 68uC (3 min
for genomic PCR), and a final extension for 10 min at 72uC. Two
mL of each PCR amplification were run on 1.5% agarose gel,
stained with GelRed (Biotium), and photographed.
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